Skip to main content
OpenTrials
Completed

NCT Number: NCT02020317

Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions

To investigate the impact of reminders for serum potassium monitoring and of hyperkalemia alerts during potassium-increasing drug-drug-interactions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperkalemia Metabolic Diseases Nutritional and Metabolic Diseases Water-Electrolyte Imbalance

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Zurich, Center for Clinical Research, Research Center for Medical Informatics

Zurich, Canton of Zurich, 8091, Switzerland

About this study

The development of hyperkalemia during potassium-increasing drug-drug-interactions (DDIs) is associated with (i) unknown or elevated serum potassium level at onset of treatment and (ii) insufficient monitoring of serum potassium during therapy. However, potassium-increasing DDIs are frequently started despite an unknown or elevated serum potassium level, and monitoring intervals often exceed 48 hours.

This study investigates the impact of reminders for serum potassium monitoring and hyperkalemia alerts. Both reminders and alerts are displayed in the electronic patient chart of in-patients treated with potassium-increasing DDIs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • in-patients treated with concurrent potassium-increasing drugs

Exclusion criteria

  • outpatients; in-patients on wards without computerized physician order entry (i.e. patients treated in the ICU)

Treatment and study plan

decision support in potassium-inc. drug-drug-interactions

Behavioral

display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts

Primary outcomes

  1. Impact on serum potassium monitoring during potassium-increasing drug-drug-interactions

    Time frame: 1 year

    Rate of serum potassium monitoring intervals of < = 72 hours during potassium-increasing drug-drug-interactions in proportion to all serum potassium monitoring intervals during potassium-increasing drug-drug-interactions

Secondary outcomes

  1. Frequency of hyperkalemia during potassium-increasing drug-drug-interactions

    Time frame: 1 year

  2. Frequency of potassium-increasing drug-drug-interactions ordered in the presence of hyperkalemia

    Time frame: 1 year

  3. Frequency of transfers to the ICU during potassium-increasing drug-drug-interactions in function of the serum potassium level

    Time frame: 1 year

  4. Frequency of death during potassium-increasing drug-drug-interactions in the presence or absence of hyperkalemia

    Time frame: 1 year

  5. Change in frequency distribution of serum potassium monitoring intervals

    Time frame: 1 year

  6. Response of physicians to the computer-based alerts and reminders

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Dec 24, 2013
Registry last updated
Jun 8, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.